1. Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
   null Palanisamy Sivanandy et al, 2020, Journal of Pharmacy and Nutrition Sciences CrossRef
2. Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines
   Erika Powe et al, 2022, Frontiers in Pharmacology CrossRef
3. Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype
   M. V. Giuli et al, 2019, Journal of Oncology CrossRef
4. Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
   Kitti Andreidesz et al, 2021, International Journal of Molecular Sciences CrossRef
5. Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair
   Marina Gobbe Moschetta-Pinheiro et al, 2022, Anti-Cancer Agents in Medicinal Chemistry CrossRef
6. A Drug Screening Reveals Minocycline Hydrochloride as a Therapeutic Option to Prevent Breast Cancer Cells Extravasation across the Blood–Brain Barrier
   Joana Godinho-Pereira et al, 2022, Biomedicines CrossRef
7. Nischarin Deletion Reduces Oxidative Metabolism and Overall ATP: A Study Using a Novel NISCHΔ5-6 Knockout Mouse Model
   Tina H. Nguyen et al, 2022, International Journal of Molecular Sciences CrossRef
8. Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
   Fokhrul Hossain et al, 2021, Cancers CrossRef